Thalia Therapeutics PLC
0GO
Company Profile
Business description
Thalia Therapeutics PLC is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Its pipeline includes a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a) [Lp(a)], which are established risk factors for cardiovascular disease.
Contact
2 Portman Street
LondonW1H 6DU
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Competition restrains long-term margins.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,953.20 | 0.90 | -0.01% |
| CAC 40 | 8,114.84 | 0.00 | 0.00% |
| DAX 40 | 24,292.38 | 337.82 | 1.41% |
| Dow JONES (US) | 49,499.27 | 152.87 | -0.31% |
| FTSE 100 | 10,363.93 | 14.89 | -0.14% |
| HKSE | 25,776.53 | 335.31 | -1.28% |
| NASDAQ | 25,114.44 | 222.13 | 0.89% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 12,995.57 | 43.63 | -0.33% |
| S&P 500 | 7,230.12 | 21.11 | 0.29% |
| S&P/ASX 200 | 8,725.00 | 0.60 | -0.01% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |